2. Academic Validation
  3. Tumor Metabolism-Rewriting Nanomedicines for Cancer Immunotherapy

Tumor Metabolism-Rewriting Nanomedicines for Cancer Immunotherapy

  • ACS Cent Sci. 2023 Sep 22;9(10):1864-1893. doi: 10.1021/acscentsci.3c00702.
Xiao Dong 1,  Shu Xia 1,  Shubo Du 2,  Mao-Hua Zhu 3,  Xing Lai 3,  Shao Q Yao 4,  Hong-Zhuan Chen 5,  Chao Fang 3 6
Affiliations

Affiliations

  • 1 Department of Pharmacy, School of Medicine, Shanghai University, Shanghai 200444, China.
  • 2 School of Bioengineering, Dalian University of Technology, Dalian 116024, China.
  • 3 Hongqiao International Institute of Medicine, Tongren Hospital and State Key Laboratory of Systems Medicine for Cancer, Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025 China.
  • 4 Department of Chemistry, National University of Singapore, Singapore 117543, Singapore.
  • 5 Institute of Interdisciplinary Integrative Biomedical Research, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203 China.
  • 6 Key Laboratory of Basic Pharmacology of Ministry of Education & Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi 563003, China.
PMID: 37901179 DOI: 10.1021/acscentsci.3c00702
Abstract

Cancer Immunotherapy has become an established therapeutic paradigm in oncologic therapy, but its therapeutic efficacy remains unsatisfactory in the majority of Cancer patients. Accumulating evidence demonstrates that the metabolically hostile tumor microenvironment (TME), characterized by acidity, deprivation of oxygen and nutrients, and accumulation of immunosuppressive metabolites, promotes the dysfunction of tumor-infiltrating immune cells (TIICs) and thereby compromises the effectiveness of immunotherapy. This indicates the potential role of tumor metabolic intervention in the reinvigoration of antitumor immunity. With the merits of multiple drug codelivery, cell and organelle-specific targeting, controlled drug release, and multimodal therapy, tumor metabolism-rewriting nanomedicines have recently emerged as an attractive strategy to strengthen antitumor immune responses. This review summarizes the current progress in the development of multifunctional tumor metabolism-rewriting nanomedicines for evoking antitumor immunity. A special focus is placed on how these nanomedicines reinvigorate innate or adaptive antitumor immunity by regulating glucose metabolism, amino acid metabolism, lipid metabolism, and nucleotide metabolism at the tumor site. Finally, the prospects and challenges in this emerging field are discussed.

Figures